Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
It is produced by the liver and plays a crucial role in many body processes
Semaglutide is a 31-amino-acid GLP-1 receptor agonist the foundation compound, characterised across the STEP obesity trials (0.25 2.4 mg weekly), the SUSTAIN type 2 diabetes programme (0.5 / 1.0 mg weekly), and SELECT (cardiovascular outcomes in obesity without diabetes)
Pair that with strength training or resistance work and regular movement
Branded GLP-1s are mass-produced, standardized medications that have undergone individual FDA approval through large-scale clinical trials for specific uses
Additionally, the medication influences appetite-regulating centers in the brain, further helping you manage your eating habits and calorie consumption effectively
